– EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults and children (≥2 years) with NF1-PN, a rare genetic disorder with debilitating symptoms –
– EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults and children (≥2 years) with NF1-PN, a rare genetic disorder with debilitating symptoms –
NEW YORK, July 18, 2025 /PRNewswire/ -- According to a new comprehensive report from The Insight Partners, the global technetium-99m market is witnessing substantial...
NEW YORK, July 18, 2025 /PRNewswire/ -- According to a new comprehensive report from The Insight Partners, the global technetium-99m market is witnessing substantial...
CIRB-led vote comes as uncertainty from strike activity increased financial losses to almost $10 million a day in June
OTTAWA, ON, July 16, 2025 /CNW/...
"Highlighting Strategic Alliances and Innovation, the Global GPCR Targeting Market Report Explores the Role of GPCRs in Drug Discovery and Therapeutics, Featuring Key Players...
20/20 Tax Resolution's new Spanish helpline offers free consultations to help Hispanic taxpayers resolve IRS and state tax issues like debt, levies, and wage...
As previously announced on July 8, 2025, the upcoming reverse share split could not be carried out due to unforeseen technical issues beyond Fingerprint Cards AB’s (publ) (“FPC” or the “Company”) control and the Company withdrew the resolution for the record date planned to be held on July 11, 2025.
TOKYO, July 15, 2025 /PRNewswire/ -- Fujitsu Limited and Acer Medical Inc., a provider of AI-powered medical imaging and preventative medicine, today announced a...
TOKYO, July 16, 2025 /PRNewswire/ -- Fujitsu Limited and Acer Medical Inc., a provider of AI-powered medical imaging and preventative medicine, today announced a...
TOKYO, July 16, 2025 /PRNewswire/ -- Fujitsu Limited and Acer Medical Inc., a provider of AI-powered medical imaging and preventative medicine, today announced a...
SHANGHAI, July 16, 2025 /PRNewswire/ -- In the newly released "Paediatric drug optimization for respiratory syncytial virus (PADO-RSV) meeting report" by Global Accelerator for...
SHANGHAI, July 16, 2025 /PRNewswire/ -- In the newly released "Paediatric drug optimization for respiratory syncytial virus (PADO-RSV) meeting report" by Global Accelerator for...